This feature articles commemorates the 10-year anniversary of the FDA's first approval of an SGLT2 inhibitor on March 29, 2013 and provides a snapshot at the class's ascent into the treatment algorithms and guidelines for type 2 diabetes, heart failure, and chronic kidney disease.

Related Keywords

United States , American , Eli Lilly , Steve Nissen , Steve Greene , Kathy Wolski , Jane Davis , Natalie Bellini , Diana Isaacs , Kim Zuber , Drug Administration , University Of Alabama At Birmingham , European Society Of Cardiology Congress , American Academy Of Nephrology Physician Assistants , Lab Us Published , A Silver Lining For Cardiometabolic Health , Diabetes Technology Program At University Hospitals , Diabetes Work Group , York Heart Association , Duke Clinical Research Institute , Johnson , Metabolic Care Center , Collaborative Group , Astrazeneca , Diabetes Technology Program , University Hospitals Diabetes , Silver Lining , New England Journal , New York Heart Association , European Society , Cardiology Congress , Triple Crown , American Academy , Nephrology Physician Assistants , Diabetes Dialogue , Real World Perspectives , May Predispose , Heart Failure , American College , American Heart Association Joint Committee , Clinical Practice Guidelines , Improving Global Outcomes , Diabetes Work , Practice Guideline , Diabetes Management , Chronic Kidney , Diabetes Mellitus Evaluating Cardiovascular Risk , New Antidiabetic Therapies , Treat Type , Federal Register , Published December , Published August , Cardiovascular Outcomes , Renal Events , Reduced Ejection , Preserved Ejection , Renal Outcomes ,